Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis and Roche. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.